TWST

Twist Bioscience Corp (TWST) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended March 31, 2026 (Q2 Fiscal 2026). Twist Bioscience Corporation provides customizable solutions across the biological continuum, utilizing a proprietary silicon-based platform for DNA synthesis, protein solutions, and next-generation sequencing (NGS) applications. The company serves over 3,800 customers in therapeutics, diagnostics, and academic research sectors.

Key Financial Metrics

Note: Cash and short-term investments as of March 31, 2026, totaled $171.7 million ($122.7 million cash + $49.0 million short-term investments).

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 19.3% year-over-year (YoY) for the quarter and 18.1% YoY for the six-month period. Growth was driven by a 28% increase in DNA synthesis and protein solutions and a 12% increase in NGS applications.
• Margin Expansion: Gross margin improved to 51.6% (Q2) and 51.8% (YTD) compared to 49.6% and 49.0% in the prior year, attributed to revenue scale and process improvements.
• Expense Fluctuations:
  • R&D Expenses: Decreased 18% YoY (Q2) and 19% YoY (YTD), largely due to the sale of the DNA data storage business in the prior fiscal year.
  • SG&A Expenses: Increased 19% YoY (Q2) and 22% YoY (YTD) due to headcount additions and investments in commercial infrastructure.
  • Litigation Costs: A one-time charge of $7.2 million was recorded for litigation settlement costs, net of recoveries, in Q2 2026. No such costs were recorded in the prior year.
• Product Shipments: Genes shipped increased 32% to approximately 300,000 in Q2 2026 compared to 227,000 in Q2 2025.

Guidance, Outlook, and Risks

• Strategic Investment: In February 2026, the company entered a $33.8 million commitment with Invenra Inc., acquiring a co-exclusive license for a bispecific antibody discovery platform and a 6.24% equity stake. $5.0 million was paid in cash; the remainder was settled or is contingent on stock issuance.
• Liquidity: Management expects current cash and short-term investments to fund operations for at least 12 months. The company has an accumulated deficit of $1.39 billion.
• Outlook: Management anticipates SG&A expenses to moderate in the second half of fiscal 2026 due to cost-saving initiatives.
• Risks & Contingencies:
  • Legal Proceedings: A securities class action lawsuit was settled in principle for approximately $17.1 million. The company expects insurance to cover the majority, with a $7.2 million net charge recognized in Q2. A derivative action remains stayed pending the class action resolution.
  • Market Risks: Risks include competition, regulatory changes, and the ability to achieve profitability.

Key Facts for Investor Verification

• Litigation Settlement: Verify the final court approval of the $17.1 million securities class action settlement and the extent of insurance recoveries.
• Invenra Transaction: Monitor the completion of the technology transfer required to finalize the $5.0 million contingent stock issuance and the integration of the B-Body platform.
• SG&A Trajectory: Track the effectiveness of cost-saving initiatives to confirm the projected moderation of SG&A expenses in H2 2026.
• Cash Burn Rate: Assess the sustainability of the current cash position ($171.7 million) against the operating cash burn of $42.4 million over the last six months.
• Revenue Mix: Confirm the continued growth in the "Therapeutics" and "Diagnostics" segments, which now represent the majority of revenue.